8 results about "Pulmonary metastasis" patented technology

The invention provides a conformation-locked amphibian skin peptide derivative or a pharmaceutically acceptable salt thereof. The conformation-locked amphibian skin peptide derivative or the pharmaceutically acceptable salt thereof has a structural formula shown in the specification or a structural analogue thereof, x is derived from one amino acid in TLa, the sequence of the TLa is LLRHVVKILEKYL, and (X) 3 is composed of any continuous sequences in three TLa. The invention also provides a preparation method of the tumor microenvironment response type TLa derivative-STING agonist MSA-2 conjugate and an application of the tumor microenvironment response type TLa derivative-STING agonist MSA-2 conjugate in tumor immunotherapy. In-vivo experiments show that the conjugate can effectively inhibit primary tumor growth and distal pulmonary metastasis in a melanoma model, and tumors of part of mice can completely fade away. The conjugate disclosed by the invention is expected to be developed into a novel efficient and low-toxicity tumor immunotherapy drug.

The invention belongs to the technical field of microorganisms, and particularly discloses an anesthesia coating spore as well as a preparation method and application thereof. The coating spore comprises a spore and a ferric iron-propofol coating attached to the body surface of the spore, and the coating is formed through metal-phenol complexing and pi-pi stacking. The spores are dormant bodies of collagenase-producing bacteria. The coating spores can be selectively germinated and colonized in a tumor hypoxic microenvironment, Fe < 3 + > can promote bacterial proliferation, loaded propofol inhibits tumor metastasis by inhibiting migration and invasion of tumor cells, generated collagenase degrades tumor collagen, meanwhile, Fe < 3 + > is reduced into Fe < 2 + > by glutathione in the cells, and the coating spores can be selectively colonized in the tumor hypoxic microenvironment. Therefore, a powerful Fenton reaction is induced to trigger lipid peroxidation, and ferroptosis of tumor cells is initiated. The injection of the anesthetic coating spores in the single tumor not only effectively ablates the primary tumor and inhibits the growth of the tumor, but also significantly inhibits the distal pulmonary metastasis of the in-situ tumor model.

This invention belongs to the field of biomedical technology and discloses the application of olaparib in combination with taquimod in the preparation of anti-tumor metastasis drugs. This invention is the first to discover that olaparib and taquimod, even at low concentrations (i.e., concentrations that do not affect tumor cell proliferation), can effectively inhibit the invasion and metastasis of breast cancer cells, exhibiting high safety. Furthermore, when olaparib and taquimod are used in combination, the inhibitory effect on breast cell invasion and metastasis shows a synergistic enhancement trend, with significantly better efficacy than single-drug therapy, overcoming the limitations of monotherapy. Moreover, the combination of olaparib and taquimod can effectively inhibit lung metastasis of breast cancer, providing a new theoretical basis and medication regimen for anti-metastasis treatment of breast cancer.

The present invention belongs to the technical field of cancer immunotherapy and specifically relates to a combination-therapy drug and composition of a cholesterolylated TLR7 liposome and a TLR9 agonist and use thereof. Toll-like receptor agonists have poor targeting capability and significant side effects in anti-tumor treatment, and, as monotherapy in anti-tumor treatment, have limited efficacy. To address the described issues, the present invention provides the cholesterolylated TLR7 liposome, which is prepared from the cholesterol-modified 1V209 molecule 1V209-Cho, a lipid component, and cholesterol, and uses the liposome in combination with the TLR9 agonist to treat tumors. Animal results show that the combination of the liposome and the TLR9 agonist, when administered as nasal drops or by means of intramuscular injection, can significantly inhibit pulmonary metastasis of cervical cancer cells and melanoma cells, indicating that using the cholesterolylated liposome 1V209-Cho-Lip in combination with the TLR9 agonist to treat tumors is a strategy with great potential.

The invention provides an application of an HOXA3 gene as a target spot in screening and treating drugs for hepatocellular carcinoma. Through single-cell multi-omics analysis, the HOXA3 is found to be remarkably and highly expressed in liver cancer tissues and is closely related to poor prognosis of patients. Mechanism research shows that HOXA3 promotes tumor proliferation and metastasis through transcriptional up-regulation of YAP1 and RHOA, and an FGF19-FGFR4 / beta-catenin signal channel positively regulates the expression of HOXA3. The invention verifies that the combined application of the YAP1 inhibitor Verteporfin and the RHOA inhibitor Rhosin can significantly inhibit the HOXA3-mediated liver cancer progress, in-vivo experiments show that the tumor volume is reduced by 68%, the lung metastasis inhibition rate reaches 83%, and an effective treatment strategy is provided for HOXA3 positive hepatocellular carcinoma.

The invention belongs to the technical field of biological detection, and particularly relates to a biomarker for detecting intestinal cancer or evaluating lung metastasis risk of intestinal cancer and application of the biomarker. Based on the biomarker serum SEMA3C, the AUC of intestinal cancer pulmonary metastasis evaluation reaches 0.867, the sensitivity is 90.2%, the specificity is 70.7%, and compared with a traditional tumor marker, the biomarker is better, and can effectively perform early diagnosis on intestinal cancer pulmonary metastasis.

The invention belongs to the related field of cancer prevention and treatment, and provides application of nicotinic acid in preparation of drugs for preventing or treating esophageal squamous carcinoma, and the drugs comprise drugs for inhibiting in-situ growth of esophageal squamous carcinoma and / or metastasis of any organ. The invention finds that high expression of FRMD8 in esophageal squamous carcinoma tissues prompts metastasis and poor prognosis. Nicotinic acid can significantly inhibit the expression level of FRMD8, thereby inhibiting the activity of a downstream JAK1-STAT3 axis. The invention finds that the nicotinic acid can significantly inhibit the in-vitro growth and invasion migration ability of esophageal squamous carcinoma cells, and can inhibit the growth and lung metastasis of esophageal squamous carcinoma cells in a mouse model.

The invention discloses a chemotherapeutic drug-loaded embolism microsphere as well as a preparation method and application of the chemotherapeutic drug-loaded embolism microsphere. The preparation method comprises the following steps: carrying out free radical polymerization cross-linking curing on a water-phase material containing macromolecules with cross-linking groups and an oil-phase material through a micro-channel pipeline to obtain microspheres; and mixing the microspheres with a chemotherapeutic drug to obtain the embolism microspheres carrying the chemotherapeutic drug. In transarterial chemical embolism treatment, by using the embolism microspheres loaded with the chemotherapeutic drugs, liver tumors can be effectively embolized, meanwhile, the entrapped chemotherapeutic drugs are slowly released, the growth of in-situ liver cancer is remarkably inhibited, and the occurrence of pulmonary metastasis is effectively reduced. The embolism microsphere capable of loading the chemotherapeutic drugs has the advantages of being high in safety, convenient to prepare, good in embolism effect and the like, efficient entrapment and controllable release of various chemotherapeutic drugs can be achieved, the embolism microsphere has large transformation potential in the field of transarterial chemical embolism of liver cancer, and development of vascular embolism agents is expected to be promoted.